8-K filed Jun 1, 2026 at 16:22 ET
Esperion Therapeutics filed an 8-K reporting the results of its 2026 annual meeting of stockholders held on May 28, 2026. Stockholders approved all four proposals, including the re-election of two Class I directors (J. Martin Carroll and Sheldon L. Koenig), a non-binding advisory vote on executive compensation, ratification of Ernst & Young as independent auditor, and a Fourth Amendment to the 2022 Stock Option and Incentive Plan increasing authorized shares by 7,000,000 to a total of 30,150,000 shares. This is a routine post-meeting filing with no material financial impact.